Resolaris regulatory update

aTyr said FDA granted Fast Track designation to Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B). Resolaris, a protein therapy based on non-canonical functions of secreted forms of aminoacyl tRNA synthetases, has completed a Phase Ib/II trial to treat patients with LGMD2B or facioscapulohumeral muscular dystrophy (FSHD). The product is also in Phase Ib/II testing to treat early onset FSHD. Resolaris has Fast Track and Orphan Drug designations in the U.S. to treat FSHD...